Matthew Ferguson - Aziyo Biologics Chief Officer
| AZYODelisted Stock | USD 2.44 0.00 0.00% |
Insider
Matthew Ferguson is Chief Officer of Aziyo Biologics
| Age | 55 |
| Phone | 240 247 1170 |
| Web | https://www.aziyo.com |
Matthew Ferguson Latest Insider Activity
Tracking and analyzing the buying and selling activities of Matthew Ferguson against Aziyo Biologics stock is an integral part of due diligence when investing in Aziyo Biologics. Matthew Ferguson insider activity provides valuable insight into whether Aziyo Biologics is net buyers or sellers over its current business cycle. Note, Aziyo Biologics insiders must abide by specific rules, including filing SEC forms every time they buy or sell Aziyo Biologics'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Matthew Ferguson over two months ago Disposition of 17000 shares by Matthew Ferguson of Elutia subject to Rule 16b-3 | ||
Matthew Ferguson over three months ago Disposition of 50000 shares by Matthew Ferguson of Elutia subject to Rule 16b-3 |
Aziyo Biologics Management Efficiency
The company has return on total asset (ROA) of (0.2875) % which means that it has lost $0.2875 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (7.7514) %, meaning that it created substantial loss on money invested by shareholders. Aziyo Biologics' management efficiency ratios could be used to measure how well Aziyo Biologics manages its routine affairs as well as how well it operates its assets and liabilities.Aziyo Biologics currently holds 34.89 M in liabilities with Debt to Equity (D/E) ratio of 3.5, implying the company greatly relies on financing operations through barrowing. Aziyo Biologics has a current ratio of 0.98, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Note, when we think about Aziyo Biologics' use of debt, we should always consider it together with its cash and equity.
Similar Executives
| Showing other executives | INSIDER Age | ||
| Mark Quick | Orthofix Medical | N/A | |
| Keith Simeone | STRATA Skin Sciences | N/A | |
| Bart Bracy | Anika Therapeutics | N/A | |
| Leigh Salvo | IRIDEX | N/A | |
| Andrew Green | Artivion | 52 | |
| David MD | Nexalin Technology | 62 | |
| Jeremy Hayden | Sight Sciences | 54 | |
| Jean Holloway | Artivion | 63 | |
| Kendra Wong | LENSAR Inc | 44 | |
| Matthew Getz | Artivion | 55 | |
| Michelle Scharfenberg | Avanos Medical | N/A | |
| Rajbir Denhoy | Establishment Labs Holdings | 53 | |
| Amy Horton | Artivion | 50 | |
| Darrell Rigel | STRATA Skin Sciences | 73 | |
| Jesse Selnick | Sight Sciences | N/A | |
| Ehab Esmail | Orthofix Medical | 52 | |
| Daniel Bevevino | Artivion | 61 | |
| Fuad Ahmad | IRIDEX | 54 | |
| Marilyn Elson | Nexalin Technology | 71 | |
| Charles III | Anika Therapeutics | N/A | |
| John Liu | Sight Sciences | N/A | |
Management Performance
| Return On Equity | -7.75 | |||
| Return On Asset | -0.29 |
Aziyo Biologics Leadership Team
Elected by the shareholders, the Aziyo Biologics' board of directors comprises two types of representatives: Aziyo Biologics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Aziyo. The board's role is to monitor Aziyo Biologics' management team and ensure that shareholders' interests are well served. Aziyo Biologics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Aziyo Biologics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Erica Elchin, VP Operations | ||
| Matthew Ferguson, Chief Officer | ||
| Randal Mills, Pres CoFounder | ||
| MS MBA, Ex Chairman | ||
| Michelle Williams, Chief Officer | ||
| Jeffry Hamet, Treasurer Fin | ||
| Sonali Fonseca, Head Buses | ||
| Courtney Guyer, VP Marketing | ||
| Thomas Englese, Chief Officer |
Aziyo Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Aziyo Biologics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -7.75 | |||
| Return On Asset | -0.29 | |||
| Profit Margin | (0.70) % | |||
| Operating Margin | (0.50) % | |||
| Current Valuation | 40.69 M | |||
| Shares Outstanding | 11.92 M | |||
| Shares Owned By Insiders | 2.18 % | |||
| Shares Owned By Institutions | 70.44 % | |||
| Number Of Shares Shorted | 68.02 K | |||
| Price To Book | 13.34 X |
Pair Trading with Aziyo Biologics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Aziyo Biologics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Aziyo Biologics will appreciate offsetting losses from the drop in the long position's value.Moving against Aziyo Stock
| 0.69 | EC | Ecopetrol SA ADR | PairCorr |
| 0.61 | BA | Boeing Fiscal Year End 29th of January 2025 | PairCorr |
| 0.57 | SHG | Shinhan Financial | PairCorr |
| 0.5 | MRK | Merck Company Fiscal Year End 6th of February 2025 | PairCorr |
| 0.39 | WF | Woori Financial Group | PairCorr |
The ability to find closely correlated positions to Aziyo Biologics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Aziyo Biologics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Aziyo Biologics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Aziyo Biologics to buy it.
The correlation of Aziyo Biologics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Aziyo Biologics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Aziyo Biologics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Aziyo Biologics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in manufacturing. You can also try the Latest Portfolios module to quick portfolio dashboard that showcases your latest portfolios.
Other Consideration for investing in Aziyo Stock
If you are still planning to invest in Aziyo Biologics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Aziyo Biologics' history and understand the potential risks before investing.
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets |